Novo Nordisk's 3rd-qtr net profit rises 11%
Danish group Novo Nordisk has posted an 11% rise in net profit to 1.25 million billion kroner ($215.1 million), or 3.69 kroner per diluted share, for the third quarter of 2004, ended September 30, on higher inventories and rising turnover of insulin analogues.
The company generated sales of 7.5 billion kroner for the period, marking a 12% rise over the year-ago quarter and leading to an 11% hike in gross profit to 5.4 billion kroner.
Commenting on the firm's results for the period, chief executive Lars Sorensen said: "the strong underlying performance continued in the third quarter, primarily driven by increased sales of insulin analogues and NovoSeven (eptacog alfa [activated]). We are furthermore very encouraged by the possibility of filing in Europe already next year for the use of NovoSeven in intracerebral hemorrhages, a condition for which today there is no effective therapy."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze